Overview
flowchart TD
companies_neuromit_pharmaceuti["NeuroMit Pharmaceuticals"]
style companies_neuromit_pharmaceuti fill:#4fc3f7,stroke:#333,color:#000
companies_neuromit_p_0["Pipeline Overview"]
companies_neuromit_pharmaceuti -->|"includes"| companies_neuromit_p_0
style companies_neuromit_p_0 fill:#81c784,stroke:#333,color:#000
companies_neuromit_p_1["Lead Program: NM-401"]
companies_neuromit_pharmaceuti -->|"includes"| companies_neuromit_p_1
style companies_neuromit_p_1 fill:#ef5350,stroke:#333,color:#000
companies_neuromit_p_2["Mechanism of Action"]
companies_neuromit_pharmaceuti -->|"includes"| companies_neuromit_p_2
style companies_neuromit_p_2 fill:#ffd54f,stroke:#333,color:#000
companies_neuromit_p_3["Scientific Rationale"]
companies_neuromit_pharmaceuti -->|"includes"| companies_neuromit_p_3
style companies_neuromit_p_3 fill:#ce93d8,stroke:#333,color:#000
companies_neuromit_p_4["Clinical Development"]
companies_neuromit_pharmaceuti -->|"includes"| companies_neuromit_p_4
style companies_neuromit_p_4 fill:#4fc3f7,stroke:#333,color:#000
companies_neuromit_p_5["Second Program: NM-501"]
companies_neuromit_pharmaceuti -->|"includes"| companies_neuromit_p_5
style companies_neuromit_p_5 fill:#81c784,stroke:#333,color:#000
...Overview
Mermaid diagram (expand to render)
NeuroMit Pharmaceuticals is a clinical-stage biotechnology company dedicated to developing mitophagy-modulating therapeutics for the treatment of neurodegenerative diseases, with an initial focus on Parkinson's disease. The company was founded in 2019 and is headquartered in Cambridge, Massachusetts["@neuromit"].
NeuroMit's lead program, NM-401, is a first-in-class oral small molecule that enhances mitophagy through a novel mechanism targeting the FUNDC1 receptor pathway. The company is also developing NM-501, a dual-action molecule that promotes both mitophagy and mitochondrial biogenesis.
Pipeline Overview
| Program | Mechanism | Indication | Phase | Status |
|---------|-----------|------------|-------|--------|
| NM-401 | FUNDC1 mitophagy activator | Parkinson's Disease | Phase 2 | Active |
| NM-501 | Mitophagy + biogenesis dual activator | Parkinson's Disease | Phase 1 | Recruiting |
| NM-601 | Receptor-mediated mitophagy | Alzheimer's Disease | Preclinical | IND-enabling |
| NM-701 | Alternative mitophagy pathway | ALS | Discovery | Research |
Lead Program: NM-401
Mechanism of Action
NM-401 is an oral small molecule that enhances mitophagy through the FUNDC1 receptor pathway:
- FUNDC1 Activation: NM-401 binds to and activates the FUNDC1 receptor on the outer mitochondrial membrane, initiating mitophagy even under conditions where PINK1-Parkin pathway is partially impaired
- LC3 Recruitment: Activated FUNDC1 recruits LC3/GABARAP proteins through its LIR (LC3-interacting region) motif
- Autophagosome Formation: The activated receptor promotes the formation of mitophagosomes that engulf damaged mitochondria
- Lysosomal Fusion: The mitophagosomes fuse with lysosomes for degradation of mitochondrial cargo
Scientific Rationale
The FUNDC1 pathway provides an alternative mitophagy mechanism complementary to PINK1-Parkin:
- PINK1-Parkin Independence: FUNDC1-mediated mitophagy can proceed even when PINK1 or parkin function is impaired, offering therapeutic benefit in genetic forms of PD[@fundcmediated2020]
- Hypoxia Response: FUNDC1 is activated under hypoxic conditions relevant to the substantia nigra microenvironment
- Calcium Modulation: The pathway responds to calcium signals, relevant to the calcium handling abnormalities in dopaminergic neurons[@fundc2019]
- Neuroprotection: Enhanced FUNDC1 mitophagy protects against mitochondrial toxins in cellular and animal models
Clinical Development
NM-401 is advancing through clinical trials:
Phase 1 Study (2022-2023): Single and multiple ascending dose study in 96 healthy volunteers established safety, tolerability, and pharmacokinetic profiles. The compound achieved therapeutic concentrations in cerebrospinal fluid[@phase2023].
Phase 2 Study (2024-2025): A 12-month, randomized, double-blind, placebo-controlled study in 240 patients with early Parkinson's disease (Hoehn & Yahr 1-2). Key endpoints include:
- Change in MDS-UPDRS parts I-III
- [Mitochondrial](/mechanisms/mitochondrial-dysfunction) function biomarkers (fibroblast bioenergetics)
- Mitophagy markers in peripheral blood mononuclear cells
- Neuroimaging: dopamine transporter binding (DaTscan)
Open-Label Extension: Active with >180 patients continuing treatment.
Second Program: NM-501
Dual-Action Mechanism
NM-501 represents a novel approach combining mitophagy enhancement with mitochondrial biogenesis:
- Mitophagy Component: Similar mechanism to NM-401, enhancing FUNDC1-mediated mitophagy
- Biogenesis Component: Activates PGC-1α signaling to promote the creation of new healthy mitochondria
- Synergistic Effect: The combination helps maintain the mitochondrial pool by both clearing damaged mitochondria and generating new ones
Clinical Development
NM-501 entered Phase 1 clinical trials in 2025:
- Single and multiple ascending dose in healthy volunteers
- Biomarker assessments for both mitophagy and mitochondrial biogenesis
- Safety and tolerability as primary endpoints
NeuroMit has developed proprietary screening capabilities:
| Assay | Application |
|-------|-------------|
| FUNDC1-LC3 interaction | Primary screening for activators |
| Mitochondrial clearance | Functional assessment |
| Patient-derived neurons | Disease-relevant models |
| In vivo mitophagy reporters | Tissue-specific analysis |
Biomarker Strategy
The company uses multi-modal biomarkers:
Functional Biomarkers: Fibroblast and PBMC bioenergetics ( Seahorse analysis)
Molecular Biomarkers: Mitophagy markers (LC3-II, p62, FUNDC1 phosphorylation)
Clinical Biomarkers: Neurofilament light chain (NfL), cytokines
Imaging: DaTscan, MRI spectroscopyMitochondrial Dysfunction in Parkinson's Disease
Therapeutic Target Rationale
Mitophagy impairment is a key feature of PD pathogenesis:
| PD Form | Mitophagy Defect | Therapeutic Approach |
|---------|-----------------|----------------------|
| Sporadic PD | Age-related decline | Enhancement (NM-401) |
| PINK1 mutations | PINK1 loss | Alternative pathway (FUNDC1) |
| Parkin mutations | Parkin loss | Alternative pathway (FUNDC1) |
| LRRK2 mutations | Variable | Enhancement (NM-401) |
Competitive Landscape
| Company | Program | Mechanism | Stage |
|---------|---------|-----------|-------|
| KeifeRx | KFR-001 | PINK1-Parkin activator | Phase 1 |
| MitoThera | MT-101 | Antioxidant | Phase 2 |
| NeuroMit | NM-401 | FUNDC1 activator | Phase 2 |
| Vandria | VNA-100 | Mitochondrial modulator | Preclinical |
- Headquarters: Cambridge, Massachusetts, USA
- Founded: 2019
- Funding: Series A ($40M, 2019), Series B ($75M, 2022), Series C ($120M, 2024)
- Investors: Flagship Pioneering, Google Ventures, The Michael J. Fox Foundation
- Partnerships: Academic collaboration with McKnight Brain Institute; pharma partnership discussions ongoing
Cross-References
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Mitochondrial Dysfunction in Parkinson's Disease](/mechanisms/mitochondrial-dysfunction-parkinsons)
- [Mitophagy in Neurodegeneration](/mechanisms/mitophagy-neurodegeneration)
- [FUNDC1 Pathway](/mechanisms/fundc1-pathway)
See Also
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Mitochondrial](/mechanisms/mitochondrial-dysfunction) Dysfunction
- [Mitophagy](/mechanisms/mitophagy)
- [Neurodegeneration](/diseases/neurodegeneration)